병원 감염 관리 시장

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Centers for Disease Control and Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), US Food & Drug Administration (FDA), European Centre for Disease Prevention and Control (ECDC), World Health Organization (WHO) Global Health Observatory, National Healthcare Safety Network (NHSN), Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Joint Commission International (JCI), International Nosocomial Infection Control Consortium (INICC), Society for Healthcare Epidemiology of America (SHEA), Association for Professionals in Infection Control and Epidemiology (APIC), Healthcare Infection Society (HIS), EU Eurostat Health Database, Organization for Economic Co-operation and Development (OECD) Health Statistics, and national health ministry reports from key markets.

Antimicrobial resistance trends, clinical safety studies, sterilization equipment, disinfectants, antiseptics, automated hand hygiene systems, UV disinfection technologies, antimicrobial coatings, and point-of-care diagnostic solutions were all gathered from these sources.

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from manufacturers of infection control devices, sterilizing equipment, disinfectants, and antiseptics, as well as OEMs, were examples of supply-side sources. Infection preventionists, hospital epidemiologists, chief nursing officers, directors of sterile processing departments, procurement leads from acute care hospitals, long-term care facilities, ambulatory surgery centers, and clinics were among the demand-side sources. In addition to gathering information on clinical adoption patterns, pricing strategies, reimbursement dynamics, and infection control protocol compliance, primary research verified product pipeline timings and validated market segmentation.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping and device deployment analysis. The methodology included:

Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Product mapping across sterilization equipment, disinfectants, antiseptics, automated hand hygiene systems, UV disinfection technologies, antimicrobial coatings, negative pressure isolation systems, and point-of-care diagnostics

Analysis of reported and modeled annual revenues specific to infection control portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (device unit sales × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across infection types (surgical site infections, catheter-associated urinary tract infections, central line-associated bloodstream infections, ventilator-associated pneumonia, Clostridioides difficile infections), pathogen types (bacterial, viral, fungal), control measures (antibiotics, antiseptics, disinfectants, isolation, vaccination), end-user settings (hospitals, clinics, long-term care facilities, ambulatory surgical centers), and technology platforms (ultraviolet light disinfection, negative pressure isolation, automated hand hygiene dispensers, antimicrobial coatings, point-of-care diagnostics)